Nippon Shokakibyo Gakkai Zasshi
Online ISSN : 1349-7693
Print ISSN : 0446-6586
Volume 67, Issue 7
Displaying 1-6 of 6 articles from this issue
  • [in Japanese]
    1970 Volume 67 Issue 7 Pages 521-524
    Published: 1970
    Released on J-STAGE: December 26, 2007
    JOURNAL FREE ACCESS
    Download PDF (545K)
  • 1. Alterations of Blood Metabolite Levels in a Glucose Tolerance Test
    Eiichi Miyata
    1970 Volume 67 Issue 7 Pages 525-539
    Published: 1970
    Released on J-STAGE: December 26, 2007
    JOURNAL FREE ACCESS
    Measurements of the concentration of pyruvate, lactate, citrate, α-ketoglutarate, NEFA, glucose and IRI in blood of patients with liver diseases including acute hepatitis (icteric phase and convalescence), chronic hepatitis (active and inactive form), cirrhosis of the liver, fatty liver and diabetes mellitus revealed the following:
    1) The enzymatically determined fasting value of blood pyruvate increased significantly in patients with acute hepatitis (icteric phase and convalscence), chronic hepatitis (inactive form), fatty liver and cirrhosis of the liver (types A, A' and B), confirming the reported results obtained by colorimetric analysis.
    2) The increased blood pyruvate level was not necessarily associated with further pronounced increase in 30 or 60 minutes after a 30g oral glucose load. The case with a high fasting pyruvate level, except for acute hepatitis (icteric phase) and cirrhosis of the liver, showed rather a decrease in pyruvate concentration at 120 minutes of the glucose load below the fasting level. Therefore, the increased fasting pyruvate value associated with its decrease below the fasting level at 120 minutes after the glucose load was characteristic of the patients with acute hepatitis (convalescence), chronic hepatitis (inactive form) and fatty liver, and the high fasting pyruvate value associated with its retarded restoration to the fasting or normal 120-minute level after the glucose load was characteristic of the patients with acute hepatitis (icteric phase) and was also found in cirrhosis of the liver and diabetes mellitus. A normal fasting pyruvate value and a higher 120-minute level than the fasting was frequently seen in patients with diabetes mellitus, chronic hepatitis (active form) and cirrhosis of the liver.
    3) These results together with the result of other blood metabolites estimation suggest that the relative rate of increased pyruvate production from glycogen (in fasting) or glucose (in glucose load) to impairment in pyruvate metabolism in mitochondria is important in the control of blood pyruvate levels in liver diseases.
    Download PDF (2039K)
  • Part I: Aldolase isozyme in the sera of the patients with various liver diseases
    Yasuharu Makisaka
    1970 Volume 67 Issue 7 Pages 540-546
    Published: 1970
    Released on J-STAGE: December 26, 2007
    JOURNAL FREE ACCESS
    The aldolase activities toward Fructose-l. 6-diphosphate (FDP-ALD) and Fructose-I phosphate (FIP-ALD) were assayed by the method of spectrophotometric measurement of reduced nicotinamide adenine dinucleotide (NADH) at 340mμ in the sera of the patients with various liver diseases and in the supernatant fluid from the homogenates of the various tissues of normal adult rats. Zone electrophoresis of aldolase isozyme in the sera of the patients described above and of the patients with malignant tumor was carried out on cellulose acetate strips.
    The results were the following:
    1. FDP-ALD activity was remarkable in the skeletal muscle, moderate in the liver and brain, and slight in the lung, kidney, and spleen of the normal rats. but FIP-ALD activity was remarkable in the liver and slight in the other tissues. FDP-ALD/FIP-ALD activity ratio (FDP/FIP) was remarkable in the skeletal muscle (45.92±2.88) and slight in the liver (1.19±0.007). In other tissues, it was moderate.
    2. Normal human serum showed the FDP-ALD activity of 5.01±1.71m-I.U., FIP-ALD activity of 2.47±0.67m-I.U. and FDP/FIP of 2.01±0.21, indicating that the main origin of the serum aldolase would be the liver.
    3. Aldolase activities toward both substrates were significantly increased but FDP/FIP was significantly decreased in each serum of the patients with acute hepatitis and active form of chronic hepatitis in comparison with those in the normal human serum. This fact suggested that the increase of this enzyme in these diseases was derived from damaged liver,
    4. Slight increase of aldolase activities toward both substrates and nearly the same ratio of FDP/FIP were observed in each serum of the patients with non-active form of chronic hepatitis and liver cirrhosis in comparison with those in the normal human serum.
    5. Electrophoretic patterns of aldolase isozyme in the sera of the patients with various liver diseases and with malignant tumor using both substrates showed unexpectedly only one band at the α2-β globurin area of the normal human serum protein.
    Download PDF (1175K)
  • Part II: Aldolase isozyme in the sera and tissues of the patients with malignant tumor
    Yasuharu Makisaka
    1970 Volume 67 Issue 7 Pages 547-553
    Published: 1970
    Released on J-STAGE: December 26, 2007
    JOURNAL FREE ACCESS
    The aldolase activities toward Fructose-1, 6-diphosphate (FDP-ALD) and Fructose-1-phosphate (FIP-ALD) were assayed by the method of spectrophotometric measurement of reduced nicotinamide adenine dinucleotide (NADH) at 340mμ in the sera of the patients with malignant tumor. Zone electrophoresis of aldolase isozyme in the supernatant fluid from the homogenates of normal human liver, skeletal muscle and human hepatoma was carried out on cellulose acetate strips.
    The results were the following:
    1. The electrophoretic patterns of aldolase isozyme from the hepatoma were nearly the same as those from skeletal muscle and different from those from normal liver using both substrates.
    2. Seventy-three percent of the patients with malignant tumor showed significant increase of FDP-ALD/FIP-ALD activity ratio (FDP/FIP) in comparison with FDP/FIP of normal human serum. This fact suggested that this enzyme in the circulation was released from the malignant tissue.
    3. The grade of increase in FDP-ALD activity was almost the same in the sera of the patients with malignant tumor but the decrease in FIP-ALD activity was different. FIP-ALD activity was slightly increased in the serum of the patient with hepatoma but decreased in the sera of the patients with other malignant tumor in comparison with those in the normal human serum. From these results, it is possible to differentiate the patient with hepatoma from the patients with other malignant tumor.
    4. FIP-ALD activity in the serum of the patient with gastric cancer with liver metastasis was higher than that in the serum of the patient with gastric cancer without liver metastasis.
    Download PDF (877K)
  • [in Japanese], [in Japanese], [in Japanese], [in Japanese], [in Japane ...
    1970 Volume 67 Issue 7 Pages 554-558
    Published: 1970
    Released on J-STAGE: December 26, 2007
    JOURNAL FREE ACCESS
    Download PDF (697K)
  • [in Japanese], [in Japanese], [in Japanese], [in Japanese], [in Japane ...
    1970 Volume 67 Issue 7 Pages 559-564
    Published: 1970
    Released on J-STAGE: December 26, 2007
    JOURNAL FREE ACCESS
    Download PDF (1910K)
feedback
Top